Certara (NASDAQ:CERT) Upgraded to "Overweight" at Barclays

Certara (NASDAQ:CERT - Get Free Report) was upgraded by equities researchers at Barclays from an "equal weight" rating to an "overweight" rating in a note issued to investors on Thursday,Briefing.com Automated Import reports. The brokerage presently has a $14.00 price objective on the stock. Barclays's target price points to a potential upside of 22.16% from the stock's current price.

A number of other equities research analysts have also weighed in on CERT. TD Cowen assumed coverage on shares of Certara in a research note on Thursday, February 27th. They set a "buy" rating and a $16.00 target price for the company. Stephens reissued an "overweight" rating and issued a $17.00 target price on shares of Certara in a report on Thursday, February 27th. JMP Securities reissued a "market perform" rating on shares of Certara in a research report on Tuesday. KeyCorp increased their price objective on shares of Certara from $15.00 to $18.00 and gave the stock an "overweight" rating in a research note on Wednesday, April 16th. Finally, William Blair reissued a "market perform" rating on shares of Certara in a report on Thursday, February 27th. Three research analysts have rated the stock with a hold rating and five have issued a buy rating to the company. Based on data from MarketBeat, the stock currently has an average rating of "Moderate Buy" and an average price target of $15.67.

Certara Trading Up 0.8 %

Certara stock opened at $11.46 on Thursday. Certara has a one year low of $8.64 and a one year high of $17.76. The business's fifty day moving average is $11.67 and its 200 day moving average is $11.66. The stock has a market capitalization of $1.85 billion, a PE ratio of -57.30, a price-to-earnings-growth ratio of 9.29 and a beta of 1.57. The company has a debt-to-equity ratio of 0.28, a current ratio of 2.86 and a quick ratio of 2.86.

Certara (NASDAQ:CERT - Get Free Report) last announced its quarterly earnings results on Monday, May 5th. The company reported $0.14 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $0.10 by $0.04. Certara had a negative net margin of 8.34% and a positive return on equity of 3.43%. The firm had revenue of $106.00 million for the quarter, compared to the consensus estimate of $104.44 million. During the same quarter last year, the firm posted $0.10 EPS. The business's quarterly revenue was up 9.7% compared to the same quarter last year. On average, sell-side analysts predict that Certara will post 0.28 EPS for the current year.

Institutional Investors Weigh In On Certara

Several hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Kopion Asset Management LLC boosted its position in shares of Certara by 46.0% in the fourth quarter. Kopion Asset Management LLC now owns 555,643 shares of the company's stock worth $5,918,000 after purchasing an additional 175,005 shares during the period. Principal Financial Group Inc. lifted its stake in shares of Certara by 3.1% during the 4th quarter. Principal Financial Group Inc. now owns 531,445 shares of the company's stock valued at $5,660,000 after buying an additional 15,739 shares in the last quarter. Vontobel Holding Ltd. bought a new position in Certara in the 4th quarter worth $1,295,000. Barclays PLC increased its stake in Certara by 198.3% in the 3rd quarter. Barclays PLC now owns 70,525 shares of the company's stock worth $825,000 after buying an additional 46,880 shares in the last quarter. Finally, Raymond James Financial Inc. bought a new stake in Certara during the fourth quarter valued at about $3,628,000. 73.96% of the stock is owned by hedge funds and other institutional investors.

About Certara

Certara, Inc, together with its subsidiaries, provides software products and technology-enabled services to customers for biosimulation in drug discovery, preclinical and clinical research, regulatory submissions, and market access in the United States and internationally. It offers solutions for model-informed drug development, as well as biosimulation solution used to predict both pharmacokinetics and pharmacodynamics.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.